Related Experiment Videos
A recombinant E. coli bioprocess for hyaluronan synthesis.
Zichao Mao1, Hyun-Dong Shin, Rachel Chen
1School of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA.
Applied Microbiology and Biotechnology
|March 25, 2009
Summary
Engineered Escherichia coli efficiently produces hyaluronic acid (HA) by co-expressing key enzymes. Supplementing precursors and decoupling HA synthesis from cell growth significantly boosted production, identifying targets for future metabolic engineering.
Area of Science:
- Biotechnology
- Microbial Engineering
- Biopolymer Production
Background:
- Hyaluronic acid (HA) is a valuable biopolymer with diverse applications.
- Efficient and scalable production of HA remains a challenge.
- Recombinant microbial systems offer a promising alternative for HA synthesis.
Purpose of the Study:
- To engineer an Escherichia coli strain for efficient hyaluronic acid (HA) production.
- To investigate methods for enhancing HA yield through metabolic engineering strategies.
- To identify limitations and optimization targets in the HA biosynthesis pathway.
Main Methods:
- Co-expression of Pasteurella multocida class-II HA synthase and E. coli uridine diphosphate-glucose dehydrogenase in E. coli JM109.
- Optimization of fermentation conditions, including fed-batch processes and pure oxygen supplementation.
- Investigation of precursor supply by supplementing glucosamine.
- Decoupling HA synthesis from cell growth using fosfomycin.
Main Results:
- Engineered E. coli produced 0.5 g/L HA in shake flasks and 2.0-3.8 g/L in fed-batch fermentation.
- Glucosamine supplementation increased HA yield by 37% and reduced oxygen demand by 42%.
- Fosfomycin treatment enhanced HA synthesis by 70%, indicating precursor competition with cell growth.
Conclusions:
- A recombinant E. coli strain was successfully developed for efficient HA production.
- Precursor supply and energy metabolism are critical factors influencing HA synthesis.
- Metabolic engineering strategies targeting precursor availability and decoupling from cell growth show significant potential for improving HA yields.
Related Concept Videos
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:27Upstream Processing
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...